Warfarin pharmacogenetics in patients with heart valve replacement

Bezci K., Cevik M., Akdeniz C. S., Canbolat I. P., Yurdakul S., SÜNBÜL M., ...Daha Fazla

GENE REPORTS, cilt.20, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.genrep.2020.100769
  • Dergi Adı: GENE REPORTS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, BIOSIS, EMBASE
  • Anahtar Kelimeler: Warfarin, CYP2C9, Heart valve replacement, Polymorphism, REDUCTASE COMPLEX SUBUNIT-1, VITAMIN-K ANTAGONISTS, BLEEDING COMPLICATIONS, GENE POLYMORPHISMS, ANTICOAGULANT-THERAPY, CYP2C9 POLYMORPHISM, ATRIAL-FIBRILLATION, VKORC1, ASSOCIATION, VARIABILITY
  • Marmara Üniversitesi Adresli: Evet

Özet

Background: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin.